Mastiha (Pistacia lentiscus) Improves Gut Microbiota Diversity, Hepatic Steatosis, and Disease Activity in a Biopsy‐Confirmed Mouse Model of Advanced Non‐Alcoholic Steatohepatitis and Fibrosis

Aimo Kannt, Efstathia Papada, Claire Kammermeier, Giuseppe D’Auria, Nuria Jiménez‐Hernández, Martin Stephan, Uwe Schwahn, Andreas Nygaard Madsen, Mette V. Østergaard, George Dedoussis, M. Pilar FrancinoMolecular 2019 · DOI

TL;DR

This study investigates the potential of Mastiha, a natural supplement derived from the Pistacia lentiscus tree, to treat non-alcoholic steatohepatitis (NASH) and fibrosis. Researchers found that Mastiha supplementation significantly improved liver health markers, reduced disease activity, and partially restored gut microbiota diversity in a mouse model of advanced NASH. This suggests Mastiha could be a promising therapeutic agent for this growing health concern.

What Problem Does This Paper Address?

Non-alcoholic fatty liver disease (NAFLD), and its more severe form, non-alcoholic steatohepatitis (NASH), are increasingly prevalent globally, largely driven by the obesity epidemic. NASH is characterized by liver inflammation and damage, and can progress to fibrosis, cirrhosis, and even liver cancer. Despite its widespread impact, there are currently no approved drugs for treating advanced NASH. Current management relies on lifestyle changes like diet and exercise, highlighting a critical need for effective therapeutic interventions. This paper addresses this unmet need by exploring the potential of Mastiha, a traditional herbal remedy, as a novel treatment for NASH and fibrosis.

Methods

The researchers utilized a well-established diet-induced obesity and NASH mouse model (DIO-NASH) in C57BL/6J mice. After inducing advanced NASH and fibrosis over 41 weeks, the mice were divided into groups: one receiving the NASH-inducing diet with 0.2% Mastiha, and a control group receiving only the NASH-inducing diet.

Key techniques employed include:

  • Histological Analysis: Liver biopsies and terminal samples were stained (hematoxylin and eosin, Sirius Red) to assess hepatic steatosis, inflammation, and fibrosis. The NAFLD activity score (NAS) and fibrosis stage were quantified.
  • Biochemical Assays: Plasma levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured as indicators of liver damage.
  • Gut Microbiota Analysis: Fecal DNA was extracted and subjected to 16S rRNA gene sequencing to analyze the diversity and composition of the gut microbiome. Bioinformatics tools were used for quality assessment, taxonomic assignment, and diversity metrics (e.g., Faith's phylogenetic diversity, PCoA).
  • Gene Expression Analysis: Liver tissue was used to quantify the expression of genes related to fibrosis and inflammation.

Datasets

Not discussed in the paper. The study utilized a mouse model and collected biological samples (liver tissue, plasma, fecal pellets) for analysis.

Key Insights and Ideas

  • Mastiha's Multifaceted Benefits: The study demonstrates that Mastiha doesn't just target one aspect of NASH; it shows improvements in multiple key areas: liver steatosis, inflammation (as indicated by reduced ALT), and fibrosis.
  • Gut-Liver Axis Connection: The research highlights the significant impact of Mastiha on the gut microbiome, suggesting a crucial role for the gut-liver axis in NASH progression and treatment. The partial recovery of gut microbial diversity is a particularly interesting finding.
  • Targeting Advanced Disease: A key strength of this study is that the intervention began when NASH and fibrosis were already established, mimicking a more clinically relevant scenario than studies focusing on prevention.
  • Potential for Non-Pharmacological Intervention: Mastiha, as a natural supplement, offers a potential avenue for non-pharmacological management of NASH, which is highly desirable given the lack of approved drugs.

Key Results

  • Reduced Liver Damage: Mastiha supplementation significantly reduced circulating ALT activity (a marker of liver injury).
  • Improved Liver Histology: Mastiha treatment led to improvements in hepatic steatosis and collagen content, and a significant reduction in the NAFLD activity score (NAS). Specifically, 60% of Mastiha-treated mice showed an improved NAS, with no worsening observed, compared to only 9% of controls.
  • Partial Gut Microbiota Recovery: Mastiha supplementation resulted in a partial but significant recovery of gut microbiota diversity. While not fully restoring diversity to lean control levels, it did promote a significant increase compared to NASH vehicle mice.
  • Changes in Microbial Composition: Mastiha treatment led to changes in the abundance of specific bacterial taxa, notably a decrease in Bacteroidia and an increase in Deltaproteobacteria. These changes were associated with NASH-related parameters.
  • No Significant Weight Change: Importantly, these improvements occurred without significant changes in body weight, suggesting a direct effect on the liver rather than being solely due to weight loss.

Limitations and Future Work

  • Extrapolation to Humans: The authors acknowledge that the results from this mouse model may not be directly extrapolated to humans, particularly regarding the high dietary cholesterol content (2%) and the absence of severe hepatocyte ballooning injury in the model.
  • Mechanisms of Action: While the study shows promising results, the precise mechanisms by which Mastiha exerts its beneficial effects, particularly on the gut microbiome and liver, require further investigation.
  • Clinical Trials: The authors emphasize the need for further studies in human NASH patients to confirm these findings and explore the therapeutic potential of Mastiha.
  • Advanced Fibrosis: The model did not fully replicate advanced fibrosis, and future studies could explore Mastiha's effects in models with more severe fibrotic stages.

Summary updated

Abstract

This is the first study demonstrating an improvement in disease activity in mice with advanced NASH with fibrosis by a diet containing Mastiha.
BibTeX
@inproceedings{kannt2019mastiha,
  author = {Aimo Kannt and Efstathia Papada and Claire Kammermeier and Giuseppe D’Auria and Nuria Jiménez‐Hernández and Martin Stephan and Uwe Schwahn and Andreas Nygaard Madsen and Mette V. Østergaard and George Dedoussis and M. Pilar Francino},
  title = {{Mastiha (<i>Pistacia lentiscus</i>) Improves Gut Microbiota Diversity, Hepatic Steatosis, and Disease Activity in a Biopsy‐Confirmed Mouse Model of Advanced Non‐Alcoholic Steatohepatitis and Fibrosis}},
  booktitle = {Molecular},
  year = {2019},
  doi = {10.1002/mnfr.201900927},
}
Figure